ArticleJournal of molecular histology2025
DLGAP5 facilitates glioblastoma growth and tumor-associated macrophage M2 polarization.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complement system-related gene signatures implicated in the recurrence of glioma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human discs large-associated protein 5 (DLGAP5), also known as DLG7, is a crucial protein associated with the mitotic spindle and is increased in different types of tumours. Nevertheless, its role in glioblastoma (GBM) remain poorly understood. Therefore, the purpose of this work was to examine the mechanisms and biological functions of DLGAP5 in GBM. Furthermore, we investigated how DLGAP5 affected the polarisation of tumor-associated macrophages (TAMs). We assessed the growth, migration, and invasion of GBM cells using a cell counting kit (CCK8), 5-Ethynyl-2'-deoxyuridine (EdU) incorporation, wound healing, and Transwell assays. The expression levels of TAM-associated differentiation markers CD68, CD206, and CD11b were examined by flow cytometry. The effects of tumour cell-derived DLGAP5 on THP-1 macrophage polarisation were investigated using a coculture paradigm including GBM cells and differentiated THP-1 cells. The effect of DLGAP5 on carcinogenesis in vivo was also investigated using a xenograft nude mice model. DLGAP5 was found to be upregulated in both GBM tissues and cell lines. The knockdown of DLGAP5 inhibited GBM cell proliferation, migration, and invasion, as well as M2 polarization of TAMs. In an in vivo model, suppression of DLGAP5 led to decreased tumor growth. Our findings indicate that DLGAP5 significantly promotes the malignant phenotype of GBM. These findings have potential implications for the future diagnosis and therapy of GBM.
Indexed as
Identifiers
40944860What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.